Akeso

Akeso's lung cancer drug ivonescimab showed better-than-expected clinical results for treating a type of lung cancer common in smokers. Analysts believe it could become a backbone therapy in the US$20 billion global non-small cell lung cancer market and raised target prices. Phase three trials found the drug reduced the risk of death.

Akeso's drug ivonescimab showed better-than-expected clinical results for treating a type of lung cancer common in smokers, potentially expanding its approved uses. Analysts predict it could become a backbone therapy in the US$20 billion global non-small cell lung cancer market, with revised upward target prices.

Akeso is increasing the production of a cancer drug. The company aims to enhance manufacturing capacity for the treatment.

The article reports that RevMed received a standing ovation at the ASCO annual meeting, while Akeso faced caution. The event's plenary session concluded, but the conference continues with further sessions and a virtual recap.

An experimental lung cancer drug developed by Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial conducted in China, according to recently released data.